Generated by AI
Virax Biolabs Group Ltd. is a biotechnology company focused on immune response detection and the diagnosis of viral diseases. Its core work centers on T cell-based in vitro diagnostic technologies and immunology profiling tools designed to help assess immune risk related to viral and immune-mediated conditions. The company develops and commercializes diagnostic test kits and related med-tech products under the ViraxClear brand, while its ViraxImmune platform is intended to support immune profiling and the evaluation of post-viral syndromes such as Long COVID and other chronic immune dysfunction states. Virax Biolabs Group Ltd. serves healthcare and research-oriented markets where viral detection, immune assessment, and diagnostic support are important, positioning the company within the broader biotechnology and in vitro diagnostics sectors. The company is headquartered in BioCity Glasgow, United Kingdom.
WebsiteBioCity Glasgow
Lanarkshire, ML1 5UH
United Kingdom
The latest articles about VRAX.
Detailed price information for Virax Biolabs Group Ltd (VRAX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.
Detailed price information for Virax Biolabs Group Limited (VRAX-Q) from The Globe and Mail including charting and trades.
Summary of Nov 16's posts. Generated by AI.
Summary of Aug 19's posts. Generated by AI.
Summary of Nov 16's posts. Generated by AI.
Investors talking about VRAX also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.